JP2009529538A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009529538A5 JP2009529538A5 JP2008558515A JP2008558515A JP2009529538A5 JP 2009529538 A5 JP2009529538 A5 JP 2009529538A5 JP 2008558515 A JP2008558515 A JP 2008558515A JP 2008558515 A JP2008558515 A JP 2008558515A JP 2009529538 A5 JP2009529538 A5 JP 2009529538A5
- Authority
- JP
- Japan
- Prior art keywords
- implant
- sirtuin activator
- poly
- resveratrol
- biodegradable polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007943 implant Substances 0.000 claims 39
- 102000011990 Sirtuin Human genes 0.000 claims 23
- 108050002485 Sirtuin Proteins 0.000 claims 23
- 239000012190 activator Substances 0.000 claims 23
- 238000000034 method Methods 0.000 claims 15
- 229920002988 biodegradable polymer Polymers 0.000 claims 13
- 239000004621 biodegradable polymer Substances 0.000 claims 13
- 239000011159 matrix material Substances 0.000 claims 12
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 11
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 11
- 235000021283 resveratrol Nutrition 0.000 claims 11
- 229940016667 resveratrol Drugs 0.000 claims 11
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 9
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims 6
- AYMYWHCQALZEGT-ORCRQEGFSA-N butein Chemical compound OC1=CC(O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 AYMYWHCQALZEGT-ORCRQEGFSA-N 0.000 claims 6
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 claims 6
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims 6
- 229920000954 Polyglycolide Polymers 0.000 claims 5
- 239000004633 polyglycolic acid Substances 0.000 claims 5
- 229920000642 polymer Polymers 0.000 claims 5
- 238000013268 sustained release Methods 0.000 claims 4
- 239000012730 sustained-release form Substances 0.000 claims 4
- BXPBSBBFPNTFFT-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-3,6-dihydroxychromen-4-one Chemical compound OC=1C(=O)C2=CC(O)=CC=C2OC=1C1=CC=C(O)C(O)=C1 BXPBSBBFPNTFFT-UHFFFAOYSA-N 0.000 claims 3
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 claims 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims 3
- 235000011990 fisetin Nutrition 0.000 claims 3
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 claims 3
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 claims 3
- 235000008718 isoliquiritigenin Nutrition 0.000 claims 3
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims 3
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims 3
- 235000009498 luteolin Nutrition 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 claims 3
- 229920000728 polyester Polymers 0.000 claims 3
- 239000004626 polylactic acid Substances 0.000 claims 3
- 235000005875 quercetin Nutrition 0.000 claims 3
- 229960001285 quercetin Drugs 0.000 claims 3
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 229920001710 Polyorthoester Polymers 0.000 claims 2
- 229930014669 anthocyanidin Natural products 0.000 claims 2
- 235000008758 anthocyanidins Nutrition 0.000 claims 2
- 150000001765 catechin Chemical class 0.000 claims 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims 2
- 235000005487 catechin Nutrition 0.000 claims 2
- 150000001789 chalcones Chemical class 0.000 claims 2
- 235000005513 chalcones Nutrition 0.000 claims 2
- 238000001125 extrusion Methods 0.000 claims 2
- 229930003949 flavanone Natural products 0.000 claims 2
- 150000002208 flavanones Chemical class 0.000 claims 2
- 235000011981 flavanones Nutrition 0.000 claims 2
- 229930003944 flavone Natural products 0.000 claims 2
- 150000002213 flavones Chemical group 0.000 claims 2
- 235000011949 flavones Nutrition 0.000 claims 2
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 claims 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims 2
- 150000002515 isoflavone derivatives Chemical class 0.000 claims 2
- 235000008696 isoflavones Nutrition 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims 2
- 239000002745 poly(ortho ester) Substances 0.000 claims 2
- 150000001629 stilbenes Chemical class 0.000 claims 2
- 235000021286 stilbenes Nutrition 0.000 claims 2
- 235000018553 tannin Nutrition 0.000 claims 2
- 229920001864 tannin Polymers 0.000 claims 2
- 239000001648 tannin Substances 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- IFVGFQAONSKBCR-UHFFFAOYSA-N n-[bis(aziridin-1-yl)phosphoryl]pyrimidin-2-amine Chemical compound C1CN1P(N1CC1)(=O)NC1=NC=CC=N1 IFVGFQAONSKBCR-UHFFFAOYSA-N 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- -1 poly (phosphate ester Chemical class 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000004127 vitreous body Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/371,117 US20070212395A1 (en) | 2006-03-08 | 2006-03-08 | Ocular therapy using sirtuin-activating agents |
| PCT/US2007/063454 WO2007103960A1 (en) | 2006-03-08 | 2007-03-07 | Ocular therapy using sirtuin-activating agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013185851A Division JP2014028822A (ja) | 2006-03-08 | 2013-09-09 | サーチュイン活性化剤を用いる眼処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009529538A JP2009529538A (ja) | 2009-08-20 |
| JP2009529538A5 true JP2009529538A5 (enExample) | 2010-04-22 |
Family
ID=38230138
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008558515A Pending JP2009529538A (ja) | 2006-03-08 | 2007-03-07 | サーチュイン活性化剤を用いる眼処置 |
| JP2013185851A Pending JP2014028822A (ja) | 2006-03-08 | 2013-09-09 | サーチュイン活性化剤を用いる眼処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013185851A Pending JP2014028822A (ja) | 2006-03-08 | 2013-09-09 | サーチュイン活性化剤を用いる眼処置 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070212395A1 (enExample) |
| EP (1) | EP1991205A1 (enExample) |
| JP (2) | JP2009529538A (enExample) |
| AU (1) | AU2007223057B2 (enExample) |
| BR (1) | BRPI0708622A2 (enExample) |
| CA (1) | CA2643903C (enExample) |
| WO (1) | WO2007103960A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658938B2 (en) * | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| US8119159B2 (en) * | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| US20070148228A1 (en) * | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US20090169585A1 (en) * | 2003-10-23 | 2009-07-02 | Resveratrol Partners, Llc | Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US20060062690A1 (en) * | 2004-08-17 | 2006-03-23 | Polymer Technology Systems, Inc. | Apparatus and method of manufacturing bodily fluid test strip |
| BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| EP2040731A4 (en) * | 2006-06-09 | 2010-05-19 | Merrion Res Iii Ltd | SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR |
| US8846073B2 (en) | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| EP2197434A4 (en) * | 2007-09-20 | 2011-08-10 | Resveratrol Partners Llc | Compositions Containing Resveratrol for Modulating Genetic Product Concentration or Activity |
| US20090280169A1 (en) * | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
| US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| EP2276439A4 (en) | 2008-05-12 | 2013-11-27 | Univ Utah Res Found | DEVICE AND CORRESPONDING METHODS FOR INTRAOCULAR MEDICAMENT ADMINISTRATION |
| US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US9636255B2 (en) | 2009-02-13 | 2017-05-02 | Dose Medical Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| TWI480286B (zh) * | 2009-02-25 | 2015-04-11 | Merrion Res Iii Ltd | 雙膦酸鹽類組合物及藥物遞送 |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| JP5937004B2 (ja) | 2009-05-18 | 2016-06-22 | ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ | 薬剤溶出眼内インプラント |
| WO2012071476A2 (en) | 2010-11-24 | 2012-05-31 | David Haffner | Drug eluting ocular implant |
| EP2470157A1 (en) * | 2009-08-24 | 2012-07-04 | The Board of Governors for Higher Education, State of Rhode Island and Providence Plantations | Hot-melt extruded compositions containing plant-derived phenolic materials and processes for the preparation thereof |
| US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| WO2011120033A1 (en) * | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| CA2819108A1 (en) * | 2010-12-15 | 2012-06-21 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| AU2012204213A1 (en) | 2011-01-07 | 2013-06-13 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| WO2013058838A2 (en) * | 2011-06-10 | 2013-04-25 | Wong Vernon G | Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer |
| JP5848042B2 (ja) | 2011-06-29 | 2016-01-27 | 株式会社ロッテ | 眼疲労抑制組成物及びそれを含む飲食品 |
| ES2428665B1 (es) * | 2012-05-04 | 2014-10-01 | Universidad De Valladolid | Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular |
| US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| CN105188666A (zh) | 2013-04-01 | 2015-12-23 | 阿勒根公司 | 用于持续的眼内释放的微球药物递送系统 |
| TR201802759T4 (tr) | 2013-10-31 | 2018-03-21 | Allergan Inc | Prostamid içeren intraoküler implantlar ve kullanım yöntemleri. |
| JP6236304B2 (ja) * | 2013-12-04 | 2017-11-22 | ライオン株式会社 | 涙液分泌促進剤 |
| EP3148491B1 (en) | 2014-05-29 | 2020-07-01 | Glaukos Corporation | Implants with controlled drug delivery features and manufacturing method for said implants |
| TWI658828B (zh) * | 2014-10-31 | 2019-05-11 | 中國醫藥大學 | 用於舒緩及減輕近視之醫藥組合物及其製備方法與用途 |
| JP7211704B2 (ja) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤 |
| US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| LT3416654T (lt) | 2016-02-18 | 2022-01-10 | Invirsa, Inc. | 5’-adenozindifosfato ribozės (adpr) medicininis panaudojimas |
| JP7003110B2 (ja) | 2016-04-20 | 2022-01-20 | ドーズ メディカル コーポレーション | 生体吸収性眼球薬物送達デバイス |
| ES2949441T3 (es) | 2018-03-27 | 2023-09-28 | Invirsa Inc | Métodos para el uso de 5'-adenosina difosfato ribosa (ADPR) |
| WO2020115765A1 (en) | 2018-12-05 | 2020-06-11 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic composition comprising sirt1 and ampk activators for treating metabolic syndrome |
| CN117529308A (zh) * | 2019-12-19 | 2024-02-06 | 鹏达特生物科学公司 | 交联的pla基共聚物 |
| CN114917209B (zh) * | 2022-05-23 | 2024-01-23 | 广西大学 | 白皮杉醇在抗弓形虫感染的应用 |
| WO2024180472A1 (en) * | 2023-02-28 | 2024-09-06 | Alcon Inc. | Ocular inserts |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3963025A (en) * | 1974-09-16 | 1976-06-15 | Alza Corporation | Ocular drug delivery device |
| US4521210A (en) * | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| US4997652A (en) * | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US5164188A (en) * | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) * | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| WO1995003009A1 (en) * | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5443505A (en) * | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6369116B1 (en) * | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| AUPO427196A0 (en) * | 1996-12-19 | 1997-01-23 | University Of Sydney, The | A method for preventing or controlling cataract |
| ES2232005T3 (es) * | 1997-08-11 | 2005-05-16 | Allergan, Inc. | Dispositivo de implante biodegradable esteril que contiene retinoide con biocompatibilidad mejorada y metodo de preparacion. |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| AUPQ496500A0 (en) * | 2000-01-06 | 2000-02-03 | University Of Sydney, The | Kit |
| US6726918B1 (en) * | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
| US6699493B2 (en) * | 2000-11-29 | 2004-03-02 | Oculex Pharmaceuticals, Inc. | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| US20050048099A1 (en) * | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| AU2004253579B2 (en) * | 2003-07-01 | 2010-12-23 | Biomol International L.P. | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
| WO2005077176A1 (en) * | 2004-02-11 | 2005-08-25 | The Trustees Of Columbia University In The City Of New York | Anthocyanin compounds and methods of use thereof |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| AU2005240078A1 (en) * | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| BRPI0510485A (pt) * | 2004-04-30 | 2007-11-13 | Allergan Inc | implantes inibidores de tirosina cinase intravìtreos biodegradáveis |
| ES2663226T3 (es) * | 2004-06-04 | 2018-04-11 | Washington University | Procedimientos y composiciones para tratar neuropatías |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| CA2609549A1 (en) * | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
-
2006
- 2006-03-08 US US11/371,117 patent/US20070212395A1/en not_active Abandoned
-
2007
- 2007-03-07 AU AU2007223057A patent/AU2007223057B2/en not_active Ceased
- 2007-03-07 JP JP2008558515A patent/JP2009529538A/ja active Pending
- 2007-03-07 CA CA2643903A patent/CA2643903C/en not_active Expired - Fee Related
- 2007-03-07 BR BRPI0708622-9A patent/BRPI0708622A2/pt not_active IP Right Cessation
- 2007-03-07 WO PCT/US2007/063454 patent/WO2007103960A1/en not_active Ceased
- 2007-03-07 EP EP07758042A patent/EP1991205A1/en not_active Withdrawn
-
2013
- 2013-09-09 JP JP2013185851A patent/JP2014028822A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009529538A5 (enExample) | ||
| JP2007535564A5 (enExample) | ||
| Christoforidis et al. | Intravitreal devices for the treatment of vitreous inflammation | |
| JP2018171519A (ja) | 持続型薬物送達インプラント | |
| AU2007223057B2 (en) | Ocular therapy using sirtuin-activating agents | |
| JP5923493B2 (ja) | 注射可能なデポー組成物の調製方法 | |
| JP2022001582A (ja) | 眼において薬物徐放を達成する方法及び生体適合性組成物 | |
| JP2007535535A5 (enExample) | ||
| AU2016351924B2 (en) | Ocular compositions | |
| JP2007535539A5 (enExample) | ||
| AR048646A1 (es) | Implante intraocular o intravitreo biodegradable que comprende un inhibidor de tirosina quinasa y un polimero biodegradable, metodo para producirlo y medicamento correspondiente | |
| JP2008540552A5 (enExample) | ||
| JP2014156496A5 (ja) | 生分解性眼内インプラント | |
| JP2007535566A5 (enExample) | ||
| WO2002024160A2 (en) | Long acting antidepressant microparticles | |
| EP3606523A1 (en) | Niraparib formulations | |
| WO2019152989A1 (en) | Pediatric niraparib formulations and pediatric treatment methods | |
| CN101394834A (zh) | 用糖皮质激素衍生物选择性渗透后段组织来治疗眼睛 | |
| AU2020311894A1 (en) | Novel methods | |
| HRP20180129T1 (hr) | Oralno raspadajuća čvrsta jedinica doze koja sadrži estetrol komponentu | |
| JP2008542296A5 (enExample) | ||
| JP2024526919A (ja) | 結晶及び非結晶に関連付けられた急性炎症性関節炎の処置において使用する為の、コルヒチンを含有する関節内注射の為の剤形 | |
| JP2024167340A (ja) | コーティング眼用インプラント | |
| AU2011239238B2 (en) | Ocular therapy using sirtuin-activating agents | |
| JP2023530173A (ja) | 生分解性組成物およびインプラント |